PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	09/911,050			
Filing Date	07/23/2001			
First Named Inventor	James L. Bullington			
Group Art Unit	1625			
Examiner Name	Robinson, Binta M.			
Attorney Docket Number	ORT-1477			

U.S. PATENT DOCUMENTS

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Docu	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
BMK		4,618,607		Araki et al.	10-21-1986	
BUIN		5,034,395		Tamada et al.	07-23-1991	
						TEC.
						D D
						2 2
				- 1000	100	9 7002
					1/290	
					9	
	l	l	1			1

FOREIGN PATENT DOCUMENTS

				Foreign Patent Docum	nent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³ Number ⁴	KindCode ⁵		mm-dd-yyyy	passages or relevant figures appear	Т ⁶		

Examiner	Date Considered	7/23/63
Signature		92701

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE TATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

to	a collection of information unless it displays a	valid UMB control number.	
	Application Number	09/911,050`	
	Filing Date	07/23/2001	
	First Named Inventor	James L. Bullington	•
	Group Art Unit	1625	•
	Examiner Name	Robinson, Binta M.	•
	Attorney Docket Number	ORT-1477	

<i>y</i>		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Т
Initials*	No.1	publisher, city and/or country where published	•
initials	140.	publisher, city and/or country where published	
BIMU	,	GASCO, et al.: "Benzofurazanyl-and benzofuroxanyl-1,4-dihydropyridines: synthesis, structure	
POURC		and calcium entry blocker activity"; Eur J. Med. Chem (1996) 31, 3-10.	
Bin		LEONARDI et al.: "Asymmetric <i>N</i> -(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity"; Eur. J. Med. Chem. 33	
		(1998) 399-420.	
		SIRCAR et al.: "Calcium Channel Blocking and Positive Inotropic Activities of Ethyl 5-Cyano-	
PANK		1,4-dihydro-6-methly-2-[(phenylsulfonyl)methyl]-4-aryl-3-pyridine-carboxylate and Analogues. Synthesis and Structure-Activity Relationships"; J. Med. Chem. 1991, 34, 2248-2260.	

_			
		E -	
		R	
		9 2002 TH 16000	
_		RECEIVED DEC 1 9 2002 EQH CENTER 1600/290	
		8	

Examiner	V (a	Date 23/63
Signature		Considered (A) - 1/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.